fda glp-1 compounding enforcement october 2025 issued 25 warning letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Offers Clarification on Compounded

Moreover, a recent study of Medicare beneficiaries found that Black seniors were roughly one-third less likely than their white counterparts to start a GLP-1 medication, even when eligible

39 It was approved by the US FDA in 2014 to treat obesity (Saxenda , Novo Nordisk, Plainsboro, NJ, USA), after first being approved as a type 2 diabetes medication (Victoza , Novo Nordisk) in 2010 (Table 1)

This period also marks the arrival of a broader next wave of players

In these cases, your doctor may consider adjusting your GLP-1 dose or temporarily interrupting treatment

doi: 10.1038/nm1168 65 ElsonAETDotsonCDEganJMMungerSD

By indication, type 2 diabetes accounted for 87.36% revenue in 2025, but obesity and weight-management prescriptions are forecast to grow at 11.57% CAGR to 2031